Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06376604 · ClinicalTrials.gov registry record · NA

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies

A NA study of Chemotherapy Effect and Cancer - Ovarian, sponsored by L-Nutra.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06376604 is a NA study of Chemotherapy Effect and Cancer - Ovarian that is actively recruiting participants, run by L-Nutra. The registered enrollment target is 30 participants, below the 100-participant average among 7 other Chemotherapy Effect trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06376604, a NA study of Chemotherapy Effect and Cancer - Ovarian, is actively recruiting participants, sponsored by L-Nutra.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies.

Interventions

  • DRUG Chemotherapy
  • OTHER Fasting Mimicking Diet

Study Locations (1)

Tennessee

  • The University of Tennessee Medical Center - Knoxville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-09-08
Est. Completion 2025-12-30
Phase NA

Sponsor

L-Nutra

5 total trials

What the Registry Record Tells You About NCT06376604

The ClinicalTrials.gov registry entry for NCT06376604 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 7 other Chemotherapy Effect trials with a reported enrollment target (70% lower). The listed sponsor is L-Nutra, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chemotherapy Effect appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT06376604 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT06376604 about?

NCT06376604 is a clinical study titled "Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies". This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies.

What is the current status of trial NCT06376604?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-09-08. Estimated completion is 2025-12-30.

What conditions does trial NCT06376604 study?

This clinical trial studies the following conditions: Chemotherapy Effect, Cancer - Ovarian, Fasting, Intermittent, Calorie Deficiency.

What interventions are being tested in trial NCT06376604?

The interventions under investigation include: Chemotherapy (DRUG), Fasting Mimicking Diet (OTHER).

Who is sponsoring clinical trial NCT06376604?

This trial is sponsored by L-Nutra, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06376604 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chemotherapy Effect

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.